AstraZeneca PLC (AZN)vsJIN MEDICAL INTERNATIONAL LTD. Ordinary Shares (ZJYL)
AZN
AstraZeneca PLC
$185.95
-0.79%
HEALTHCARE · Cap: $282.69B
ZJYL
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares
$2.47
-13.64%
HEALTHCARE · Cap: $18.94M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 292055% more annual revenue ($60.44B vs $20.69M). AZN leads profitability with a 17.2% profit margin vs 5.8%. ZJYL trades at a lower P/E of 12.1x. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
ZJYL
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Intrinsic value data unavailable for ZJYL.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Reasonable price relative to book value
Attractively priced relative to earnings
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 3.7% — below average capital efficiency
5.8% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : ZJYL
The strongest argument for ZJYL centers on Price/Book, P/E Ratio.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : ZJYL
The primary concerns for ZJYL are Market Cap, Return on Equity, Profit Margin.
Key Dynamics to Monitor
AZN profiles as a mature stock while ZJYL is a value play — different risk/reward profiles.
ZJYL carries more volatility with a beta of 7.23 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 36/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Jin Medical International Ltd. designs and manufactures wheelchairs and living aids products.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?